Trouble viewing this email? Read it on the Web here.
Golden Helix Newsletter

 
20th Anniversary Special Offers

We have put together a total of 20 packages that offer a variety of 20-month licenses for the price of a 12-month license!

Here's a list of what we're offering

  • (2) SVS License 1 user - $2,995
  • (1) SVS Server License with Imputation 2 user - $7,995
  • (3) VarSeq License 1 user - $4,795
  • (1) VarSeq License (w/ VSReports & VS-CNV) 1 user - $12K
  • (3) VSClinical License (w/ VarSeq, VSReports, CADD & OMIM) 1 user - $12K
  • (2) VSClinical & VS-CNV License (Small Lab Starter) 2 user - $24K
  • (2) VarSeq, VSReports, VS-CNV, Tier 1 Sentieon 1 users $17.5K
  • (3) Sentieon Tier 2 License - $10K
  • (2) Small Warehouse License (VS-CNV, VSClinical, Sentieon Tier 1, VSReports, VSPipeline) 2 user - $48K
  • (1) Warehouse License (VS-CNV, VSClinical, Sentieon Tier 1, VSReports, VSPipeline) Up to 10 users - $120K

Offers end on Sept 15, or when all license packages have been purchased. To learn more about these offers, please visit /forms/EOY/20th-anniversary-deals.html.

New VarSeq Single Exome Demo Project
VSClinical: The details you should know
by Eli Sward
Field Application Scientist


The recent release of VSClinical gives users the ability to evaluate variants based on the 33 criteria according to the American College of Medical Genetic and Genomics (ACMG) guidelines. This feature leverages a variety of variant sequencing evidence including population data, functional data, and computational predictions while providing rich visualizations and auto recommendations to help answer challenging criteria. This highly sophisticated yet user-friendly technology is intuitive, but like any new software, there is a learning curve... Continue Reading »

VGolden Helix�s Twentieth Year Anniversary
Golden Helix�s Twentieth Year Anniversary
by Andreas Scherer, Ph.D
President & CEO


If we take a look back in time, a lot happened in September 1998. It is the month in which the first ever �Who wants to be a Millionaire?� show debuted on ITV in Britain. Larry Page and Sergey Brin incorporated Google in September, registering the Google.com domain on September 15, 1998. And on that very same day, we officially formed Golden Helix, Inc. as a business entity! A few days later, the Internet Corporation for Assigned Names and Numbers (ICANN) was formed... Continue Reading

 
   CEO Corner
Andreas Scherer
Golden Helix is celebrating its 20th anniversary on September 15th! We started this company well before the Human Genome Project completed and have been successfully servicing this industry ever since. Over the years we have served ten of thousands of users who, in one way or another, leveraged our software to conduct analytics on human, plant or animal data. I would like to express our utmost gratitude to all of our customers who we had the distinct pleasure to serve in the last two decades. I would also like to thank my team for all the creativity and dedication that goes into developing our products and servicing our clients. Together we are thriving to create the best possible experience for our clients. Golden Helix's pillars are innovation, quality and customer satisfaction. Our commitment to these pillars created a global, growing and very loyal customer base. It will be the key to our success in the next twenty years!

If you'd like to read more about GHI's story, you can do so by heading to my most recent blog post here.

  Upcoming Webcast

Processing Hereditary Cancer Panels in VarSeq

August 15th, 2018 | 12:00 PM EST
Processing variants related to cancer is an incredibly critical process and a primary goal is to not only assess the variants rapidly but also accurately. A major improvement to cancer panel workflow efficiency is to utilize VarSeq for variant filtering, annotating, and interpretation. In this webcast we�ll cover some important quality assurance capabilities VarSeq provides, multiple approaches to build targeted panels, how to access/utilize numerous cancer annotations, and finally work through the ACMG guideline process on the selected germline cancer variants. The overall goal is to cover the basics of building the cancer gene panel project template so that it can be used routinely in high throughput environments.

Register for the webcast here.

 
Facebook     Twitter     Linked In     Blog   YouTube


About Golden Helix
Golden Helix� is a global bioinformatics firm founded in 1998. Our largest outside investor is GlaxoSmithKline who invested early on into the company. We develop and sell an industry leading clinical solution that supports the analysis of sequencing data and the creation of clinical reports. Clinicians and researchers worldwide trust our solution. Over all these years we have accumulated a significant customer base conducting business with over 350 organizations globally with thousands of users leveraging our various analytics products. Our customers fall into five categories: Large Hospitals, Genetic Testing Labs, Pharmaceutical companies, major research organizations, and government organizations here in the US and internationally. Our work his referenced in over 1,200 publications such as Science, Nature and Nature Genetics.

Copyright 2000-2017 Golden Helix, Inc. All Rights Reserved.
Golden Helix, Inc. | 203 Enterprise, Blvd. | Bozeman, MT | 59718
View our Privacy Policy.